ID   CML-2
AC   CVCL_0D23
SY   CML2
DR   Wikidata; Q54813786
RX   PubMed=3434911;
RX   PubMed=8239507;
RX   PubMed=11467477;
RX   PubMed=12944992;
CC   Derived from site: In situ; Oral cavity, gingiva; UBERON=UBERON_0001828.
CC   Breed/subspecies: Scottish Terrier; VBO=VBO_0201198.
DI   NCIt; C185639; Canine oral melanoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
OI   CVCL_RW91 ! CML-2M
SX   Sex unspecified
AG   11Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 10-09-24; Version: 9
//
RX   PubMed=3434911; DOI=10.2460/ajvr.1987.48.11.1642;
RA   Wolfe L.G., Oliver J.L. 3rd, Smith B.B., Toivio-Kinnucan M.A.,
RA   Powers R.D., Brawner W.R., Henderson R.A., Hankes G.H.;
RT   "Biologic characterization of canine melanoma cell lines.";
RL   Am. J. Vet. Res. 48:1642-1648(1987).
//
RX   PubMed=8239507;
RA   Ahern T.E., Bird R.C., Church Bird A.E., Wolfe L.G.;
RT   "Overexpression of c-erbB-2 and c-myc but not c-ras, in canine
RT   melanoma cell lines, is associated with metastatic potential in nude
RT   mice.";
RL   Anticancer Res. 13:1365-1371(1993).
//
RX   PubMed=11467477; DOI=10.1354/vp.38-4-427;
RA   Koenig A., Wojcieszyn J., Weeks B.R., Modiano J.F.;
RT   "Expression of S100a, vimentin, NSE, and melan A/MART-1 in seven
RT   canine melanoma cells lines and twenty-nine retrospective cases of
RT   canine melanoma.";
RL   Vet. Pathol. 38:427-435(2001).
//
RX   PubMed=12944992; DOI=10.1038/sj.cgt.7700625;
RA   Bianco S.R., Sun J., Fosmire S.P., Hance K.W., Padilla M.L., Ritt M.G.,
RA   Getzy D.M., Duke R.C., Withrow S.J., Lana S., Matthiesen D.T.,
RA   Dow S.W., Bellgrau D., Cutter G.R., Helfand S.C., Modiano J.F.;
RT   "Enhancing antimelanoma immune responses through apoptosis.";
RL   Cancer Gene Ther. 10:726-736(2003).
//